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A locus on human chromosome 11q23 tagged by marker rs3802842 was associated with colorectal cancer (CRC) in a genome-
wide association study; this finding has been replicated in case–control studies worldwide. In order to identify biologic factors
at this locus that are related to the etiopathology of CRC, we used microarray-based target selection methods, coupled to
next-generation sequencing, to study 103 kb at the 11q23 locus. We genotyped 369 putative variants from 1,030 patients
with CRC (cases) and 1,061 individuals without CRC (controls) from the Ontario Familial Colorectal Cancer Registry. Two previ-
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ously uncharacterized genes, COLCA1 and COLCA2, were found to be co-regulated genes that are transcribed from opposite
strands. Expression levels of COLCA1 and COLCA2 transcripts correlate with rs3802842 genotypes. In colon tissues, COLCA1
co-localizes with crystalloid granules of eosinophils and granular organelles of mast cells, neutrophils, macrophages, dendritic
cells and differentiated myeloid-derived cell lines. COLCA2 is present in the cytoplasm of normal epithelial, immune and other
cell lineages, as well as tumor cells. Tissue microarray analysis demonstrates the association of rs3802842 with lymphocyte
density in the lamina propria (p 5 0.014) and levels of COLCA1 in the lamina propria (p 5 0.00016) and COLCA2 (tumor cells,
p 5 0.0041 and lamina propria, p 5 6 3 10–5). In conclusion, genetic, expression and immunohistochemical data implicate
COLCA1 and COLCA2 in the pathogenesis of colon cancer. Histologic analyses indicate the involvement of immune pathways.
Genome-wide association studies (GWAS) for over two
dozen cancers have identified over 150 loci that individually
confer modest increases in cancer risk, although few of these
have led to the precise identification of causal genes and
alleles.1 Of the 23 published loci associated with colorectal
cancer (CRC) predisposition,2–6 functional studies implicate
SMAD7,7 MYC,8,9 CDH110 and EIF3H,11 as well as other
plausible candidates such as BMP4 and GREM1 that are
members or modulators of the transforming growth factor
beta superfamily that regulates cell proliferation.
An important challenge in deciphering the molecular basis of
a GWAS locus is that the associated marker is a “tag” single
nucleotide polymorphism (SNP) that is in linkage disequili-
brium (LD) with many nearby SNPs.12 Even when a disease-
associated GWAS locus has a plausible candidate gene, the
mechanistic basis for the association may be complex. For exam-
ple, the lung cancer risk-associated variants on chromosome
15q25 are located in a region of strong LD that includes six
genes (CHRNB4, CHRNA5, CHRNA3, LOCI123688, PSMA4
and IREB2).13 Although the nicotinic acetylcholine receptor
genes are the top candidates due to their involvement in nicotine
addiction, IREB2 is being considered, based on its expression
levels correlating with risk genotypes and its roles in oxidative
stress and inflammation.13 By integrating genome-wide datasets
of regulatory variation to specific disease loci, several GWAS
loci appear to involve genes whose expression levels correlate
with associated variants, including SMAD7 and colon cancer,7
PSCA and bladder cancer,14 TOX3 and breast cancer,5 and genes
linked with numerous non-cancer loci.16
Here we report a high-resolution analysis of genetic variants and
candidate genes on chromosome 11q23, in the vicinity of GWAS
single nucleotide polymorphism (SNP) rs3802842. The associated
11q23 region was first reported in a Scottish study17 and subse-
quently refined to a 60 kb region using 10,638 cases and 10,457 con-
trols from Europe, North America and Australia.18 The C allele of
rs3802842 (global minor allele frequency 5 31.3% in the 1,000
Genomes Project19 was shown to predispose to CRC, with odds
ratio (OR) 5 1.17 per allele, p 5 1.08 3 10212. Replication of the
association has been reported in Dutch,20 Chinese,21 European
American and Hawaiian22 populations. A recent meta-analysis com-
prising 38,534 cases and 39,446 controls reported significant associa-
tion between rs3802842 and CRC risk (OR5 1.45).23
Material and Methods
The study was approved by the research ethics boards of the
University of Toronto and Mount Sinai Hospital, Toronto.
Sequenced samples include genomic DNA from 40 sporadic
CRC cases and 40 matched controls selected from the 2,380
samples from the Ontario Familial Colorectal Cancer Registry
(OFCCR) that were previously genotyped by GWAS24 and 25
probands and 15 affected siblings selected from pedigrees
showing autosomal dominant transmission that were selected
based on absence of mutations in genes causing familial CRC.
Genotyping of 11q23 SNPs was performed using the iSe-
lect array from Illumina. Novel SNPs that have been success-
fully genotyped and validated were submitted to dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/) under the sub-
mission handle OICR_HUDSON.
RNA expression analyses, luciferase reported assays, pro-
tein expression and histochemical studies followed common
laboratory protocols.
What’s new?
Genome-wide association studies have identified genomic loci associated with increased cancer risk, but the precise identifi-
cation of the genes supporting cancer development within these loci remains challenging. The authors performed high-
resolution mapping of a region on chromosome 11q23 previously associated with colorectal cancer predisposition. They iden-
tified COLCA1 and COLCA2, two coordinately regulated genes for which transcript and protein expression correlated with the
presence or absence of the single-nucleotide polymorphism (SNP) identified in the region. In addition, the presence of the
SNP as well as expression levels of the candidate genes correlated with a characteristic histological pattern of lymphocyte
infiltration in the lamina propria of the colon tissue. These studies link colon cancer risk with immune pathways providing
new opportunities for improved colon cancer diagnostic tools, novel predictive biomarkers, and potential therapeutic strat-
egies modulating the tumor microenvironment.
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Further methods: Detailed methods and associated tables,
figures and references are available in Supporting Information
materials.
Results
High-resolution mapping of the 11q23 CRC locus
In a panel of 120 individuals recruited in the OFCCR and
one CEPH sample, we used microarray-based target selection
coupled to next-generation sequencing,25 to interrogate
103,418 bp of DNA including exonic, intronic and intergenic
intervals at the 11q23 CRC locus. The selected region was
defined as the largest interval that includes SNPs in LD with
rs3802842 (r2 > 0.20), based on release 23a of the CEU Hap-
Map data. This defines a broad region that should contain
the causal SNP/haplotype picked up by the tag SNP. We gen-
erated 650 Mb of usable sequencing data in the target
regions, corresponding to an average of 53 reads per base of
genomic target and 72 reads per exonic base. We identified
524 putative SNPs and 64 putative insertion/deletions (indels)
(Fig. 1a and Supporting Information Table 1).
We genotyped 369 putative variants in 1,030 cases and 1,061
controls from the OFCCR, in addition to the sequenced samples.
The data revealed a high overall concordance (98.6%) between
sequence-based genotypes and array-based genotypes, although
there were many false-positives indels (80%) and a moderate
rate of false-positives for SNPs (13.5%), which generally corre-
sponded to putative variants detected at low coverage and/or
misalignment at the codon level. We confirmed two coding
non-synonymous SNPs in C11orf92 in the original sequenced
samples: (1) p.Gly22Arg for which only one additional instance
of the alternative allele was seen in an independent set of 2,091
genotyped samples and (2) p.Ala7Thr, which has an allele fre-
quency of 1.5% in cases and 1.8% in controls. Only one coding
non-synonymous SNP was discovered in C11orf93; SNP
rs201868314 was present in a subject with sporadic CRC, but
not observed in the subsequent panel of 2,091 samples.
There are signals of association at 11q23 for many SNPs in
the interval. A quantile–quantile (Q–Q) plot illustrating all sig-
nificance levels shows deviation of the weight of the distribu-
tion toward greater levels of associations (Fig. 1b). This shift in
weight is caused by LD with rs3802842. Performing tests of
association by conditioning on the presence or the absence of
the GWAS risk allele on the same haplotypes as the test alleles
shifts the Q–Q plot distribution back towards the null (Fig. 1c).
Figure 1d shows the location of all SNPs with minimum
allele frequencies above 1% in cases and controls combined
and risk of CRC in 1,030 cases and 1,061 controls, the signif-
icance levels of tests of association and comprehensive LD
maps among common variants. GWAS SNP rs3802842
reaches a significance level of p < 0.002 in this sample set. It
is noteworthy that extensive sequencing and genotyping of
the 11q23 locus in the OFCCR did not reveal other variants
that are more significant than rs3802842; several 11q23 var-
iants show similar association and are in strong LD with
rs3802842.
Expression of two transcripts at 11q23 show association
with rs3802842
The region includes three uncharacterized protein-coding
genes (C11orf53, C11orf92 and C11orf93). A nearby gene,
POU2AF1 was also deemed a candidate as it is differentially
expressed in lymphoma and leukemia.26,27 We characterized
RNA abundances of these transcripts in tissues obtained dur-
ing colon resections. We tested benign adjacent colonic tis-
sues as well as colonic tumors from individuals homozygous
for the lower risk (A) or higher risk (C) alleles of rs3802842,
or heterozygous (A/C) (Fig. 2a). Lower risk alleles correlate
with increased expression of C11orf92 and C11orf93 in
benign adjacent colonic tissues as well as in tumors. We note
increased expression of C11orf53 in tumor samples from
individuals that are associated with the number of lower risk
alleles, but no correlations are observed in benign adjacent
colonic tissue. No association with POU2AF1 is detected.
C11orf92 and C11orf93 are arranged on opposite strands
and share a regulatory region that contains genetic variants
that are in high LD with rs3802842 (Fig. 2b). To investigate
the cis-regulatory potential of the most common haplotypes
associated with lower or higher risk, we cloned three inde-
pendent triplicate DNA fragments of 4.2 kbp for each allele
of rs3802842, as well as ten additional variants (9 SNPs and
rs5794738, a 9 bp indel), into luciferase reporter vectors (Fig.
2c). When tested in both orientations, higher luciferase activ-
ity is observed for clones harboring the lower risk haplotype
compared to those with the higher risk haplotype (Fig. 2d).
COLCA1 structure and expression features
C11orf92 (Colorectal Cancer Associated 1 or COLCA1)
required further investigations of gene structure to comple-
ment annotations present in public databases (Supporting
Information Figs. 1 and 2). COLCA1 has multiple alternative
5’ non-coding exons, and one constant exon that codes for a
124-amino acid protein. COLCA1 is a primate-specific gene
(Supporting Information Fig. 3). COLCA1 does not show
homology to other proteins in public databases. Its secondary
structure is predicted to possess a signal peptide, a trans-
membrane domain (Supporting Information Fig. 4) and O-
linked glycosylation.
Protein variants for COLCA1 are rare, as confirmed by
Sanger sequencing of an additional set of cases (Supporting
Information Table 2). In silico predictions of functional corre-
lates for alleles contained on the lower/higher risk haplotypes
(Supporting Information Table 3) can be made, although their
specific role in modifying cancer risk is unknown. One of the
strongest CRC-associated variants at this locus is rs10891246
that is in LD with rs3802842 (r2 5 0.99). For COLCA1,
rs10891246 coincides with a splice site resulting in a short
and long version of exon 1, a non-coding exon (Supporting
Information Fig. 5). In a survey of COLCA1 RNA in tissue
panels representing the gastrointestinal tract and the immune
system, we observe expression from the esophagus to the
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rectum (Supporting Information Fig. 6a), multiple immune
organs (Supporting Information Fig. 6b) and other tissues
such as prostate, testis and ovary (Supporting Information
Fig. 7a). Western blot analyses provide preliminary evidence
that COLCA1 has greater expression in benign adjacent tis-
sues than in tumors obtained at the time of colon cancer or
adenoma resections (Supporting Information Fig. 8). A single
band is observed for COLCA1 in these tissues as well as
Figure 1. Association analysis of the CRC locus tagged by GWAS SNP rs3802842. (a) Polymorphism discovery, quality filters and genotyping
flow-chart for 11q23. (b) Quantile–quantile plot of significance levels against theoretical quantiles for unconditional tests of association.
Red lines represent 95% confidence bands. (c) Same plot as in (b), but with tests of association conditional on rs3802842. (d) Architecture
of the 11q23 locus. From top to bottom: base position and known genes; percentage of samples with at least 63 sequence coverage as a
function of base position; significance of tests of association, on the negative log scale, with the red dot indicating rs3802842; LD struc-
ture between all variants, with color shading showing the squared correlation coefficient r2.
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lysates from peripheral blood, eosinophils, neutrophils and
CD141 monocytes, but not in lymphocytes. We observe
greater protein expression in homozygotes having the lower
risk A allele compared to homozygotes for the C allele (Sup-
porting Information Fig. 8b).
Immunohistochemistry with anti-COLCA1 in colon tissues
reveals expression in the lamina propria, but not in normal
epithelial cells or epithelium-derived neoplastic cells (Fig. 3a).
At higher magnification (Fig. 3b), COLCA1 expression appears
to be part of granular structures. In addition, extracellular
Figure 2. RNA expression, genomic organization and promoter analyses of COLCA1 and COLCA2. (a) Relative mRNA expression levels of
11q23 transcripts in benign adjacent (BA) and tumor (T) samples as a function of the rs3802842 genotype. Error bars indicate SEM. p val-
ues are derived from one-way ANOVA followed by Student-Newman-Keuls test. *p<0.01, **p<0.001. (b) Genomic organization of C11orf92/
COLCA1 (gold) and C11orf93/COLCA2 (blue). (c) Luciferase (LUC)-based reporter constructs for COLCA1 (top) and COLCA2 (bottom). Lower
risk (LRH) and higher risk (HRH) haplotypes are depicted as blue and red bars, respectively. (d) Luminescence results in HeLa cells. Values
are expressed as mean 6 SEM for n 5 3. *p < 0.05. V is a promoter-less luciferase vector; p#1–3 denote patients 1–3.
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COLCA1 is observed in normal adjacent tissue and in some
cases the COLCA1 signal appears to infiltrate spaces between
epithelial cells. Using cryosections of both benign adjacent
colon and tumor tissues, triple immunofluorescence patterns
show strong COLCA1 expression in eosinophils and moderate
expression in mast cells, neutrophils, macrophages and dendri-
tic cells (Fig. 4a). Within all COLCA1-positive immunofluores-
cent cells, COLCA1 signal is present in granular structures.
To validate the correlations between rs3802842 and
COLCA1 staining in the lamina propria surrounding tumor
tissues (Figs. 4b and 4c), we employed a novel image analysis
method (Supporting Information Fig. 9) to quantitate
COLCA1 staining in tissue microarrays (TMAs). TMAs of
colorectal cancers representing various stages from 96
patients were stained and scored. The correlation between
the number of lower risk alleles of rs3802842 with increased
staining for COLCA1 in the lamina propria was confirmed
(Kruskal-Wallis test: p 5 0.00016; Fig. 4d).
Although COLCA1 mRNA expression is mostly observed
in cell lines of hematopoietic origin (lymphoid and myeloid)
and in some cell lines derived from epithelial tumors includ-
ing Caco-2 (colorectal adenocarcinoma) and Saos-2 (osteosar-
coma) (Supporting Information Figs. 7b and 10), COLCA1
protein was not detected in HeLa cells, four colon cancer cell
lines (including Caco-2) and a panel of lymphoid and mye-
loid cell lines (Supporting Information Figs. 11a and 11b).
We hypothesized that only differentiated hematopoietic cells
having the capacity to assemble granules would be able to
express COLCA1. We first corroborated this in an in vitro
model using human promyelocytic leukemia HL60 clone 15
Figure 3. COLCA1 and COLCA2 expression in paraffin-embedded colon biopsy samples. (a) Double immunohistochemical staining for
COLCA1 (red; hematoxylin counterstain) and tumor-specific CEA (carcinoembryonic antigen; brown), scale bars, 20 mm. (b) 1003 oil objec-
tive images (scale bars, 10 mm) of representative tissues immunostained with COLCA1 (brown; hematoxylin counterstain). (c) Double immu-
nohistochemical staining for COLCA2 (red; hematoxylin counterstain) and CEA (brown), scale bars, 20 mm.
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cells differentiated into eosinophils using n-butyrate.28
Endogenous COLCA1 protein is observed when cells are
stimulated to differentiate (Figs. 5a and 5b). In this model,
COLCA1 is heavily glycosylated (Fig. 5c), a feature common
to other granule-associated proteins.29 Several other in vitro
models can be induced to express COLCA1 protein: (1) Cord
blood mononuclear cells differentiated into CD451CD34-
CD1171CD11c-CD11b- mast cells (Supporting Information
Fig. 11c) and CD11b1CD11c1 dendritic cells (Supporting
Information Fig. 11d); (2) LAD2 mast cells30 transfected with
GFP-fused COLCA1 cDNA (Supporting Information Fig.
12a) and (3) TLS-ERG transduced CD341 TEX cells31 that
are stimulated to differentiate into eosinophil-like cells using
IL3, IL5 and GM-CSF (Supporting Information Fig. 12b).
To identify cellular compartment that contain COLCA1,
we first employed a method that causes partial membrane
permeabilization followed by differential centrifugation to
separate cytosolic, nucleosolic, nuclear insoluble and mem-
brane components of HL60 clone 15 cells treated with
n-butyrate to produce COLCA1 (Fig. 5d). COLCA1 is absent
in fractions specific to the cytosol, nucleus and cytoskeleton,
but enriched in a fraction that contains a diversity of mem-
brane proteins. We observe that COLCA1 co-sediments with
membrane proteins associated with eosinophilic granules and
secretory vesicles, including LAMP2, CD63/LAMP3, VAMP2
and VAMP7.32 Crystalloid-specific proteins (core: MBP;
matrix: EDN) are mostly detected in the membrane extract, a
pattern that could be explained by low permeabilization of
crystalloid granule membranes. Galectin-10, a primary-
granule specific protein is found in the cytosolic extract and
ECP, a matrix protein of small granules and crystalloid gran-
ules is mostly found in the cytosolic extract.32 EPO, a matrix
protein of lipid bodies and crystalloid granules32 is found in
both the cytosolic and membrane extracts. The data are con-
sistent with complete permeabilization of membranes for
lipid bodies, primary granules and small granules.
Imaging studies using HL60 clone 15 cells transfected
with GFP-COLCA1 and pre-treated with n-butyrate were
Figure 4. COLCA1 expression in immune cells in colon tissues and association with rs3802842. (a) Co-localization of COLCA1 with specific immune
cell subsets markers was assessed on cryosections from colon tumor biopsies using three-dimensional deconvolution microscopy. High-power
images of single immune cells were taken at sequential 0.1–0.3 mm z axis depth separation (scale bars, 3 mm). For all images, COLCA1 staining is
shown in red and a pan-leukocyte marker (CD45) is shown in blue. Green signals represent different immune cell-specific markers: eosinophils (Eo)
labeled with eosinophil major basic protein (MBP); mast cells (MC) labeled with mast cell tryptase; neutrophils (Neu) labeled with neutrophil elas-
tase; macrophages (Mac) labeled with MAC387; dendritic cells (DC) labeled with CD83. (b, c) Double immunohistochemical staining for COLCA1,
red and CEA, brown, in distal, proximal and tumor core of colon tissues from patients homozygous for the lower risk rs3802842 genotype (AA) (b),
compared to the higher risk genotype (CC) (c) (scale bars, 50 mm). (d) Association analyses between genotypes at rs3802842 and COLCA1 expres-
sion in TMAs. Individual expression values and corresponding boxplots are illustrated. Thick horizontal lines represent median values.
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conducted to identify eosinophil granule proteins that co-
localize with COLCA1 (Fig. 5e, Supporting Information Fig.
13). Proteins that co-localize the most with COLCA1 are
known to be associated with crystalloid granules, the most
common type of granules in eosinophils; these include the
membrane protein LAMP3, the core protein MBP and matrix
proteins EPO and ECP.32 Galectin-10, which is associated
with primary granules32 shows no co-localization with
COLCA1. VAMP-2, a specific protein associated with a class
of secretory vesicles also shows no co-localization.
COLCA2 structure and expression features
C11orf93 (Colorectal Cancer Associated 2 or COLCA2) has
several orthologs in mammals (Supporting Information Fig.
14). The revised gene model for COLCA2 includes eight
exons, with variable exons 1–4 added in various
Figure 5. Expression of COLCA1 in granules of HL60 clone 15 cells. (a) Cells were treated with n-butyrate (0.5 mM, lower panels) for 6
days, stimulated with phorbol 12-myristate 13-acetate (162 nM, right panels) for 4 hr, and immunostained for COLCA1 (red), eosinophil
major basic protein (green) and DAPI nuclear stain (blue). (b) Western blot of COLCA1 in lysates from n-butyrate treated cells. The molecular
weight of the immunoreactive signal is higher than predicted. (c) Western blot of glycosylated and deglycosylated COLCA1 in lysates from
n-butyrate treated cells in the presence or absence of PMA. (d) Western blot of COLCA1 in subcellular fractions of cells: cytosolic (CE),
membrane (ME), nuclear soluble (NSE), chromatin-bound (NCE) and cytoskeletal protein extracts (CSE). The asterisks indicate post-
deglycosylation. (e) Co-localization of COLCA1-GFP with proteins associated with eosinophil granules. Confocal immunofluorescence images
of COLCA1-GFP-transfected cells (green) immunostained with antibodies to eosinophil granule proteins (red) and counterstained with DAPI
(blue).
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combinations to constant exons 5–8 to generate a minimum
of five confirmed transcripts yielding protein isoforms rang-
ing from 154 to 379 amino acids in length (Supporting Infor-
mation Figs. 1, 15 and Supporting Information Table 4).
Additional protein isoforms are predicted from Western
blots. Immunoreactive bands ranging from 17 to 47 kDa that
potentially represent eight COLCA2 protein isoforms are
observed in different permutations in tested samples, includ-
ing colonic tissues, peripheral blood and 17 cell lines (Sup-
porting Information Fig. 16; some data not shown)
representing multiple cell types. In silico predictions of func-
tional correlates for COLCA2 variants (Supporting Informa-
tion Table 3) can be made for rs10891246, such that
isoforms having an alanine at this position correlate with the
lower risk allele while the higher risk haplotype encodes for a
threonine at this position. Another CRC-associated variant in
LD with rs3802842 is rs7105857 (r250.91); this SNP disrupts
a splice site resulting in a longer version of exon 4 and a lon-
ger protein isoform.
Western blots and immunofluorescence analyses for
COLCA2 reveal protein expression in the cytoplasm of many
cell types of epithelial (normal and tumoral), lymphoid, mye-
loid, mesenchymal (including fibroblasts) and other origins
(Figs. 3c, 6a and Supporting Information methods). We also
observe an increase in COLCA2 protein expression in colon
tissues from individuals with the lower risk AA genotype
(Figs. 6b and 6c). TMAs with this biomarker validate the
association between the lower risk allele of rs3802842 with
increased staining for COLCA2, and allow us to observe cor-
relations in two distinct areas: (1) epithelium (p 5 0.004; Fig.
6f); and (2) lamina propria (p 5 6 3 1025, Fig. 6g).
Lymphoid cell aggregates and lymphocyte density
correlate with CRC-associated variants at 11q23
Histological review of tissue sections from patients having
different genotypes at rs3802842 suggested that lymphoid cell
aggregates are more common in colon biopsies from patients
with the AA genotype. This observation was validated using
combined monoclonal antibodies for CD45 (clones 2B11 and
PD7/26) that are immunoreactive for lymphoid cells (and
mast cells) but non-reactive to polymorphonucear leukocytes
and nonhematopoietic tissues33 Figs. 6d and 6e). TMAs
stained with these anti-lymphocyte antibodies show signifi-
cant association at rs3802842 (p 5 0.014; Fig. 6h).
Discussion
Several lines of evidence link COLCA1 and COLCA2 with
CRC: (1) genetic association at 11q23; (2) correlation
between risk alleles with COLCA1 and COLCA2 RNA levels
in normal colon and CRC tissues; (3) correlation between
risk alleles with COLCA1 and COLCA2 protein levels in
CRC tissues; (4) presence in many mucosal immune cells of
the colon implicated in tumor immunity.
In this study, COLCA1 and COLCA2 were screened for
germline mutations in 40 individuals from pedigrees display-
ing autosomal dominant transmission, but no highly pene-
trant CRC mutation was discovered. An expanded analysis in
sporadic cases revealed no plausible protein-coding variant in
COLCA1 that can explain the association identified by
GWAS. A common variant (rs10891246) in high LD (r2 5
0.97) with the GWAS variant (rs3802842) codes for an ala-
nine to threonine polymorphism in COLCA2 that is present
on two protein isoforms.
We observe that several variants in a 5kb haplotype
containing rs3802842 correlate with expression levels of
COLCA1 and COLCA2. Some of the variants in high LD
with rs3802842 overlap with transcription factor binding
sites: p53/rs6589218, CREB/rs10891245, E2F/rs11213823,
FoxB1/rs4520624 and FoxB1/rs5794738 (a 9-bp deletion)
(Supporting Information Table 3). It is interesting to note
that this locus was reported to have a differential epige-
nomic profile at an enhancer overlapping rs3802842
between colon and non-colon derived tissues and cell
lines,34 leading to the hypothesis that rs3802842 may affect
enhancer function. We provided experimental evidence in
support of differential transcriptional activity for the higher
and lower risk haplotypes using luciferase reporter
constructs.
COLCA1 is a primate-specific gene whose recent evolution
may be similar to many positively selected genes among
mammals that are frequently involved in immunity and
defense. COLCA1 is present in granular organelles in eosino-
phils, mast cells, neutrophils, macrophages and dendritic cells
in the gastrointestinal microenvironment. We presented evi-
dence that COLCA1 protein expression in cell line models is
restricted to myeloid-derived cell lines that are differentiated
into granule-producing cells. Cell fractionation and imaging
co-localization studies are consistent with COLCA1 being a
membrane protein of crystalloid granules in eosinophils,
which contain the core protein MBP and matrix proteins
(EPO, EDN and ECP).32
COLCA1 is expressed in many cells having a role in
inflammation and cancer.35 The significance of eosinophils
and mast cells in cancer remain controversial, particularly for
mast cells which have been implicated in tumor promotion
through angiogenesis, tissue remodeling and regulatory T-cell
dysfunction.36,37 Mast cell depletion can lead to remission of
polyps in mouse models.38 However, mast cells may also be
damaging to tumor cells via cytokines and proteolytic
enzyme secretion. In a breast cancer study, stromal mast cells
correlate with favorable prognosis.39 The literature provides a
stronger case for eosinophils having tumoricidal functions.
Abundance of eosinophils in gastrointestinal cancers is a
favorable prognostic factor.40 Eosinophils may induce apo-
ptosis and kill tumor cells, via the release of ECP, EDN,
TNF-a and granzyme.41 Eosinophil products can degrade
necrotic materials from tumor cells through production of
reactive oxygen species.42 Eosinophils, which are the highest
expressors of COLCA1, contain granular structures that are
known to harbor pre-formed proteins. Extracellular COLCA1
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Figure 6. COLCA2 expression and lymphocyte density in colon correlates with rs3802842. (a) Co-localization of COLCA2 with cell-specific
markers was assessed on cryosections from colon tumor biopsies using three-dimensional deconvolution microscopy. High-power images
of COLCA2-positive cells were taken at sequential 0.1–0.3 mm z axis depth separation (scale bars, 5 mm). For all images, COLCA2 staining
is shown in red and DAPI is shown in blue. Green signals represent different cell-type specific markers: epithelial cells labeled for cytokera-
tin; leukocytes labeled with a pan-CD45 marker; macrophages labeled with MAC387; eosinophils (Eo) labeled with eosinophil major basic
protein (MBP); fibroblasts labeled with Thy-1. (b, c) COLCA2 expression in colon tissues. Double staining for COLCA2, red and CEA, brown,
in distal, proximal and tumor core of colon tissues from patients homozygous for the lower risk rs3802842 genotype (AA) in (b) compared
to the higher risk genotype (CC) in (c) (scale bars, 50 mm). (d, e) Double immunohistochemical staining for lymphocytes (CD45 clones 2B11
and PD7/26), red and CEA, brown, in distal, proximal and tumor core of colon tissues from patients homozygous for the lower risk
rs3802842 genotype (AA) in (d) compared to the higher risk genotype (CC) in (e) (scale bars, 50 mm). (f, g) Association analyses between
genotypes at rs3802842 and COLCA2 in colon tumor epithelial cells (f) and in the lamina propria (g). (h) Association analyses between
genotypes at rs3802842 and CD45 expression in the lamina propria. Individual expression values and corresponding boxplots are illus-
trated. Thick horizontal lines represent median values.
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staining in colon tissues has a similar pattern that has been
described for extracellular eosinophil-derived granules.43
COLCA2 is present in many cell types of epithelial, mes-
enchymal and hematopoietic origins and has orthologs in
multiple mammals. Since COLCA2 expression is reduced in
tumor cells from subjects with higher risk alleles, it is possi-
ble that COLCA2 has critical functions that suppress tumor
formation in epithelial cells. Although not characterized as a
cancer gene, we note the recent identification of two protein-
coding mutations in 2 of 25 melanoma samples.44 Higher
levels of COLCA2 in immune and other cells of the microen-
vironment may also provide protection against cancer cell
growth.
The role of genetic variation linking the immune system
with colon cancer has been recognized. Both juvenile polypo-
sis and Lynch Syndromes are caused by germline mutations
that in addition to promoting tumorigenesis within colon
epithelial cells are associated with inflammatory cell infil-
trates. Germline mutations in SMAD4 cause juvenile polypo-
sis and Smad4 mutant mice have lymphocytic and
eosinophilic infiltrates in colon tissues45 and provide evidence
that the effect of genetic mutations in intestinal lymphocytes
are important for maintaining intestinal homeostasis.46
Patients with colorectal tumors with microsatellite instability
(MSI), including heritable forms that are part of Lynch Syn-
drome are also characterized by lymphocytic infiltrates, natu-
ral antitumor immune responses47 and improved prognosis
compared with patients with non-MSI tumors.48 This is con-
sistent with other reports linking tumor-infiltrating lympho-
cytes with improved survival in colon cancer,49 independent
of MSI status.50
The characterization of novel proteins and inflammatory
processes correlating with genotypes associated with colon
cancer risk suggests that the locus may modulate a complex
network involving immune and tumor cells. It is interesting
to note that at this stage of our investigation, COLCA1 and
COLCA2 functions do not interconnect with functions of
other genes implicated in CRC. Further investigations are
needed to determine the precise functions of COLCA1 and
COLCA2 and histological changes correlating with genotypes
at 11q23.
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